Alnylam Pharmaceuticals, Inc.
Revenue Breakdown
| Fiscal Year | ONPATTRO | AMVUTTRA | GIVLAARI | OXLUMO | Collaboration and other revenue | Royalty revenue |
|---|---|---|---|---|---|---|
| FY2024 | $252.9M | $970.5M | $255.9M | $167.1M | $510.2M | $91.8M |
| FY2025 | $172.8M | $2.31B | $308.5M | $191.4M | $553.4M | $174.0M |
Revenue Breakdown
| Fiscal Year | ONPATTRO | AMVUTTRA | GIVLAARI | OXLUMO | Collaboration and other revenue | Royalty revenue |
|---|---|---|---|---|---|---|
| FY2024 | $252.9M | $970.5M | $255.9M | $167.1M | $510.2M | $91.8M |
| FY2025 | $172.8M | $2.31B | $308.5M | $191.4M | $553.4M | $174.0M |